MA33609B1 - Molecules de liaison a dll4 - Google Patents
Molecules de liaison a dll4Info
- Publication number
- MA33609B1 MA33609B1 MA34722A MA34722A MA33609B1 MA 33609 B1 MA33609 B1 MA 33609B1 MA 34722 A MA34722 A MA 34722A MA 34722 A MA34722 A MA 34722A MA 33609 B1 MA33609 B1 MA 33609B1
- Authority
- MA
- Morocco
- Prior art keywords
- molecules
- dll4
- link
- relates
- binding molecules
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
Abstract
L'invention concerne des molécules de liaison à Dll4, de préférence des domaines variables uniques d'immunoglobuline de liaison à Dll4 tels que des VHH et VH, des compositions pharmaceutiques les contenant et leur utilisation dans le traitement de maladies qui sont associées à des effets à médiation par Dll4 sur l'angiogenèse. L'invention concerne également des acides nucléiques codant pour des molécules de liaison à Dll4, des cellules hôtes et des procédés pour les préparer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09172132 | 2009-10-02 | ||
PCT/EP2010/064693 WO2011039368A2 (fr) | 2009-10-02 | 2010-10-01 | Molécules de liaison à dll4 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA33609B1 true MA33609B1 (fr) | 2012-09-01 |
Family
ID=42083895
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA34722A MA33609B1 (fr) | 2009-10-02 | 2012-03-26 | Molecules de liaison a dll4 |
Country Status (23)
Country | Link |
---|---|
US (1) | US20110195494A1 (fr) |
EP (1) | EP2483313A2 (fr) |
JP (1) | JP2013506410A (fr) |
KR (1) | KR20120115217A (fr) |
CN (1) | CN102648210A (fr) |
AP (1) | AP2012006167A0 (fr) |
AR (1) | AR078516A1 (fr) |
AU (1) | AU2010302587A1 (fr) |
BR (1) | BR112012007294A2 (fr) |
CA (1) | CA2775420A1 (fr) |
CL (1) | CL2012000818A1 (fr) |
EA (1) | EA201200549A1 (fr) |
EC (1) | ECSP12011828A (fr) |
IL (1) | IL218544A0 (fr) |
IN (1) | IN2012DN02715A (fr) |
MA (1) | MA33609B1 (fr) |
MX (1) | MX2012003797A (fr) |
NZ (1) | NZ598650A (fr) |
PE (1) | PE20121184A1 (fr) |
TN (1) | TN2012000144A1 (fr) |
TW (1) | TW201124532A (fr) |
UY (1) | UY32917A (fr) |
WO (1) | WO2011039368A2 (fr) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
US20130078247A1 (en) * | 2011-04-01 | 2013-03-28 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to dii4 and ang2 |
US8858941B2 (en) | 2011-09-23 | 2014-10-14 | Oncomed Pharmaceuticals, Inc. | VEGF/DLL4 binding agents and uses thereof |
KR101535341B1 (ko) | 2012-07-02 | 2015-07-13 | 한화케미칼 주식회사 | Dll4에 특이적으로 결합하는 신규한 단일클론항체 및 이의 용도 |
KR102089591B1 (ko) * | 2013-07-29 | 2020-03-18 | 삼성전자주식회사 | 항 EGFR scFv 단편 및 이를 포함하는 항 c-Met/항 EGFR 이중 특이 항체 |
EP3297672B1 (fr) | 2015-05-21 | 2021-09-01 | Harpoon Therapeutics, Inc. | Protéines trispécifiques de liaison et méthodes d'utilisation |
US11339213B2 (en) | 2015-09-23 | 2022-05-24 | Mereo Biopharma 5, Inc. | Methods and compositions for treatment of cancer |
US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
SG11201810327XA (en) | 2016-05-20 | 2018-12-28 | Harpoon Therapeutics Inc | Single domain serum albumin binding protein |
CA3044659A1 (fr) | 2016-11-23 | 2018-05-31 | Harpoon Therapeutics, Inc. | Proteine de liaison a l'antigene membranaire specifique de la prostate |
US10844134B2 (en) | 2016-11-23 | 2020-11-24 | Harpoon Therapeutics, Inc. | PSMA targeting trispecific proteins and methods of use |
WO2018160754A2 (fr) | 2017-02-28 | 2018-09-07 | Harpoon Therapeutics, Inc. | Protéine monovalente inductible de fixation d' antigène |
CA3063359A1 (fr) | 2017-05-12 | 2018-11-15 | Harpoon Therapeutics, Inc. | Proteines de liaison a la mesotheline |
CA3063362A1 (fr) | 2017-05-12 | 2018-11-15 | Harpoon Therapeutics, Inc. | Proteines trispecifiques ciblant la msln et procedes d'utilisation |
PT3694529T (pt) | 2017-10-13 | 2024-09-20 | Harpoon Therapeutics Inc | Proteínas triespecíficas e métodos de utilização |
JP7066837B2 (ja) | 2017-10-13 | 2022-05-13 | ハープーン セラピューティクス,インク. | B細胞成熟抗原結合タンパク質 |
CN109160948B (zh) * | 2018-09-21 | 2021-07-16 | 成都阿帕克生物科技有限公司 | 一种乙肝表面抗原纳米抗体及核酸分子和应用 |
WO2020069028A1 (fr) | 2018-09-25 | 2020-04-02 | Harpoon Therapeutics, Inc. | Protéines de liaison à dll3 et méthodes d'utilisation |
BR112022016550A2 (pt) | 2020-02-21 | 2022-11-16 | Harpoon Therapeutics Inc | Proteínas de ligação a flt3 e métodos de uso |
CN111875706B (zh) * | 2020-07-16 | 2021-03-30 | 广州康盛生物科技股份有限公司 | 一种抗人IgE蛋白的单域抗体及其应用 |
CN116547006B (zh) * | 2021-08-06 | 2024-09-20 | 贝达药业股份有限公司 | 抗pd-l1纳米抗体及其应用 |
WO2024089627A1 (fr) * | 2022-10-26 | 2024-05-02 | Berking Biotechnology Spa | Anticorps à domaine unique -sdab/vhh dirigé contre la nucléoprotéine du virus sars-cov-2 |
CN117659194B (zh) * | 2023-11-30 | 2024-08-13 | 科弈(浙江)药业科技有限公司 | 靶向egfr的纳米抗体、药物偶联物及其用途 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994004678A1 (fr) | 1992-08-21 | 1994-03-03 | Casterman Cecile | Immunoglobulines exemptes de chaines legeres |
EP0739981A1 (fr) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Fragments variables d'immunoglobulines-utilisation thérapeutique ou vétérinaire |
US6329516B1 (en) | 1997-04-28 | 2001-12-11 | Fmc Corporation | Lepidopteran GABA-gated chloride channels |
US6926898B2 (en) | 2000-04-12 | 2005-08-09 | Human Genome Sciences, Inc. | Albumin fusion proteins |
CA2433877C (fr) | 2001-01-17 | 2014-11-18 | Genecraft, Inc. | Proteines de fusion d'immunoglobuline de domaine de liaison |
DE60237282D1 (de) | 2001-06-28 | 2010-09-23 | Domantis Ltd | Doppelspezifischer ligand und dessen verwendung |
EP1463752A4 (fr) | 2001-12-21 | 2005-07-13 | Human Genome Sciences Inc | Proteines de fusion d'albumine |
EP2336179A1 (fr) | 2002-11-08 | 2011-06-22 | Ablynx N.V. | Anticorps a domaine unique stabilises |
BRPI0316092B8 (pt) | 2002-11-08 | 2021-05-25 | Ablynx Nv | anticorpos de domínio único direcionados contra o fator de necrose tumoral alfa e usos para os mesmos |
EP1578842B1 (fr) | 2002-12-31 | 2009-10-07 | Nektar Therapeutics Al, Corporation | Polymeres a terminaison maleimide hydrolytiquement stables |
PT1639011E (pt) | 2003-06-30 | 2009-01-20 | Domantis Ltd | Anticorpos (dab) de domínio único peguilados |
EP2251357A1 (fr) | 2003-11-07 | 2010-11-17 | Ablynx N.V. | Anticorps VHH de domaine unique de camélidés dirigés contre le récepteur du facteur de croissance épidermique et utilisations correspondantes |
US20050284249A1 (en) | 2004-06-29 | 2005-12-29 | Arnone David F | Worm type gear mover assembly |
CA2583017A1 (fr) | 2004-10-13 | 2006-04-20 | Ablynx N.V. | Nanocorps contre la proteine beta-amyloide et polypeptides les renfermant pour le traitement de maladies degeneratives neurales, telles que la maladie d'alzheimer |
US8048418B2 (en) * | 2004-10-29 | 2011-11-01 | Regeneron Pharmaceuticals, Inc. | Therapeutic methods for inhibiting tumor growth with combination of Dll4 antagonists and VEGF antagonists |
US20080107648A1 (en) | 2005-12-16 | 2008-05-08 | Regeneron Pharmaceuticals, Inc. | Therapeutic methods for inhibiting tumor growth with DII4 antagonists |
MX342271B (es) | 2005-05-18 | 2016-09-21 | Ablynx Nv | Nanobodiestm (nanocuerpos) mejorados contra el factor alfa de necrosis del tumor. |
JP2009539384A (ja) * | 2006-06-06 | 2009-11-19 | ジェネンテック・インコーポレーテッド | 抗dll4抗体および抗dll4抗体使用の方法 |
US20080014196A1 (en) | 2006-06-06 | 2008-01-17 | Genentech, Inc. | Compositions and methods for modulating vascular development |
CA2666599A1 (fr) | 2006-08-18 | 2008-02-21 | Ablynx N.V. | Sequences d'acides amines dirigees contre l'il-6r et polypeptides les contenant utilises pour le traitement de maladies et de troubles associes au signal medie par il-6 |
US20080132451A1 (en) * | 2006-12-01 | 2008-06-05 | Alcon Manufacturing Ltd. | Modulation of polysialylated neural adhesion molecules (psa-ncam) as a regulator of ocular disease |
NO347649B1 (no) * | 2006-12-14 | 2024-02-12 | Regeneron Pharma | Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse. |
GB0709333D0 (en) * | 2007-05-15 | 2007-06-20 | Smart Targeting Ltd | Binding protein |
WO2009095489A2 (fr) | 2008-02-01 | 2009-08-06 | Ablynx N.V. | Séquences d'acides aminés améliorées dirigées contre il-6r et polypeptides les comprenant pour le traitement de maladies et troubles associés à une signalisation facilitée par il-6 |
CA2717015A1 (fr) | 2008-03-05 | 2009-09-11 | Ablynx Nv | Nouveaux complexes dimeres de fixation a des antigenes, procedes de fabrication et utilisations associes |
-
2010
- 2010-09-30 US US12/894,947 patent/US20110195494A1/en not_active Abandoned
- 2010-09-30 UY UY32917A patent/UY32917A/es not_active Application Discontinuation
- 2010-10-01 BR BR112012007294A patent/BR112012007294A2/pt not_active IP Right Cessation
- 2010-10-01 EA EA201200549A patent/EA201200549A1/ru unknown
- 2010-10-01 AP AP2012006167A patent/AP2012006167A0/xx unknown
- 2010-10-01 KR KR20127011414A patent/KR20120115217A/ko not_active Application Discontinuation
- 2010-10-01 AR ARP100103597 patent/AR078516A1/es unknown
- 2010-10-01 PE PE2012000423A patent/PE20121184A1/es not_active Application Discontinuation
- 2010-10-01 MX MX2012003797A patent/MX2012003797A/es not_active Application Discontinuation
- 2010-10-01 JP JP2012531450A patent/JP2013506410A/ja active Pending
- 2010-10-01 CA CA 2775420 patent/CA2775420A1/fr not_active Abandoned
- 2010-10-01 IN IN2715DEN2012 patent/IN2012DN02715A/en unknown
- 2010-10-01 AU AU2010302587A patent/AU2010302587A1/en not_active Abandoned
- 2010-10-01 EP EP20100767972 patent/EP2483313A2/fr not_active Withdrawn
- 2010-10-01 WO PCT/EP2010/064693 patent/WO2011039368A2/fr active Application Filing
- 2010-10-01 TW TW99133558A patent/TW201124532A/zh unknown
- 2010-10-01 CN CN2010800548891A patent/CN102648210A/zh active Pending
- 2010-10-01 NZ NZ59865010A patent/NZ598650A/en not_active IP Right Cessation
-
2012
- 2012-03-08 IL IL218544A patent/IL218544A0/en unknown
- 2012-03-26 MA MA34722A patent/MA33609B1/fr unknown
- 2012-03-29 TN TNP2012000144A patent/TN2012000144A1/en unknown
- 2012-04-02 CL CL2012000818A patent/CL2012000818A1/es unknown
- 2012-04-25 EC ECSP12011828 patent/ECSP12011828A/es unknown
Also Published As
Publication number | Publication date |
---|---|
AR078516A1 (es) | 2011-11-16 |
AU2010302587A1 (en) | 2012-04-05 |
CL2012000818A1 (es) | 2012-10-19 |
BR112012007294A2 (pt) | 2016-11-22 |
IN2012DN02715A (fr) | 2015-09-11 |
WO2011039368A3 (fr) | 2011-06-23 |
TN2012000144A1 (en) | 2013-09-19 |
JP2013506410A (ja) | 2013-02-28 |
NZ598650A (en) | 2014-03-28 |
US20110195494A1 (en) | 2011-08-11 |
AP2012006167A0 (en) | 2012-04-30 |
CA2775420A1 (fr) | 2011-04-07 |
UY32917A (es) | 2011-04-29 |
PE20121184A1 (es) | 2012-09-16 |
TW201124532A (en) | 2011-07-16 |
EA201200549A1 (ru) | 2012-12-28 |
KR20120115217A (ko) | 2012-10-17 |
WO2011039368A2 (fr) | 2011-04-07 |
MX2012003797A (es) | 2012-06-28 |
EP2483313A2 (fr) | 2012-08-08 |
IL218544A0 (en) | 2012-05-31 |
ECSP12011828A (es) | 2012-05-30 |
CN102648210A (zh) | 2012-08-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA33609B1 (fr) | Molecules de liaison a dll4 | |
MA33607B1 (fr) | Molécules de liaison bispécifiques pour une thérapie anti-angiogénique | |
MA34979B1 (fr) | Molecules de liaisonbispecifiques se liant a vegf et ang2 | |
MA35233B1 (fr) | Molecules de liaison bispecifiques se liant à dii4 et ang2 | |
MA56289B1 (fr) | Mutéines d'interleukine-21 et méthodes de traitement | |
MA40972B1 (fr) | Molécules bispécifiques de liaison à l'antigène activant les lymphocytes t ciblant folr1 et cd3 | |
MA44547B1 (fr) | Anticorps anti-pd-1,procédé de leur production et de leur utilisation | |
MA35437B1 (fr) | Proteines de fusion pour le traitement de troubles du metabolisme | |
EA201100239A1 (ru) | Композиции, одновалетные в отношении связывания cd28, и способы их применения | |
MX2009002418A (es) | Anticuerpos para las proteinas morfogenicas oseas y receptores de estas y metodos para su uso. | |
UA116194C2 (uk) | Антитіло, яке специфічно зв'язується з людським альфа-синуклеїном | |
Rattanapisit et al. | Recombinant human osteopontin expressed in Nicotiana benthamiana stimulates osteogenesis related genes in human periodontal ligament cells | |
NO20083793L (no) | Antistoffer mot amyloid-beta peptid | |
UA112743C2 (uk) | Терапевтичний dll4-зв'язувальний білок | |
MA37983A1 (fr) | Analogues du glucagon | |
MA32928B1 (fr) | Anticorps anti-cxcr4 et leur utilisation pour le traitement du cancer | |
CO6551686A2 (es) | Inmunoglobinas con dominio variable dual y usos de las mismas | |
MX353319B (es) | Composiciones y metodos relacionados con anticuerpos del receptor de glucagon. | |
BR112013028655A8 (pt) | Anticorpos anti-fator de crescimento neuronal, composição farmacêutica compreendendo os mesmos e kit para o tratamento de dor em felinos | |
TR201908638T4 (tr) | Ang2 bağlayıcı moleküller. | |
MA38190A2 (fr) | Inhibiteurs d'autotaxine | |
MD3830120T3 (ro) | Noi proteine de fuziune specifice pentru CD137 și PD-L1 | |
MA34175B1 (fr) | Anticorps anti-cxcr4 humanisés pour le traitement de cancer | |
MA39342B2 (fr) | Anticorps il -21 | |
EA201290671A1 (ru) | Антигенсвязывающие белки, специфические в отношении сывороточного амилоидного компонента р |